GBS
MCID: GLL022
MIFTS: 59

Guillain-Barre Syndrome (GBS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Guillain-Barre Syndrome

MalaCards integrated aliases for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 12 20 43 58 36 54 42 44 15 17 70
Guillain-Barré Syndrome 73 20 43 53 3 32
Fisher Syndrome 43 53 36
Gbs 20 43 58
Acute Inflammatory Demyelinating Polyneuropathy 20 70
Acute Inflammatory Polyneuropathy 20 43
Acute Inflammatory Demyelinating Polyradiculoneuropathy 20
Acute Inflammatory Demyelinating Polyradiculopathy 12
Acute Autoimmune Peripheral Neuropathy 20
Landry-Guillain-Barre-Strohl Syndrome 20
Acute Immune-Mediated Polyneuropathy 20
Acute Postinfectious Polyneuropathy 12
Variant of Guillain-Barre Syndrome 58
Guillain-Barré-Strohl Syndrome 20
Landry-Guillain-Barre Syndrome 43
Guillain-Barre-Strohl Syndrome 58
Acute Inflammatory Neuropathy 20
Acute Infectious Polyneuritis 43
Acute Infective Polyneuritis 12
Post-Infectious Polyneuritis 12
Landry's Ascending Paralysis 20
Postinfectious Polyneuritis 12
Post-Infective Polyneuritis 20
Miller Fisher Syndrome 70
Infectious Neuronitis 12
Variant of Gbs 58

Characteristics:

Orphanet epidemiological data:

58
guillain-barre syndrome
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;
variant of guillain-barre syndrome
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:12842
MeSH 44 D020275
NCIt 50 C116345
SNOMED-CT 67 155082001
ICD10 32 G61.0
MESH via Orphanet 45 D020275
ICD10 via Orphanet 33 G61.0
UMLS via Orphanet 71 C0018378
UMLS 70 C0018378 C0393799 C3542501

Summaries for Guillain-Barre Syndrome

MedlinePlus Genetics : 43 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations.Muscle weakness or paralysis are the characteristic features of Guillain-Barré syndrome. The weakness often begins in the legs and spreads to the arms, torso, and face and is commonly accompanied by numbness, tingling, or pain. Additional signs and symptoms of the condition include difficulty swallowing and difficulty breathing. Occasionally, the nerves that control involuntary functions of the body such as blood pressure and heart rate are affected, which can lead to fluctuating blood pressure or an abnormal heartbeat (cardiac arrhythmia).There are several types of Guillain-Barré syndrome, classified by the part of the peripheral nerve involved in the condition. The most common type of Guillain-Barré syndrome is acute inflammatory demyelinating polyradiculoneuropathy (AIDP). In AIDP, the immune response damages myelin, which is the covering that protects axons and promotes the efficient transmission of nerve impulses. In two other types of Guillain-Barré syndrome, acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), the axons themselves are damaged by the immune response. In AMAN, only the axons of motor neurons are damaged. In AMSAN, the axons of sensory neurons are also damaged. Because of sensory nerve damage, affected individuals can lose the ability to sense the position of their limbs and can have abnormal or absent reflexes (areflexia).Miller Fisher syndrome, another type of Guillain-Barré syndrome, involves cranial nerves, which extend from the brain to various areas of the head and neck. Miller Fisher syndrome is characterized by three features: weakness or paralysis of the muscles that move the eyes (ophthalmoplegia), problems with balance and coordination (ataxia), and areflexia. People with this condition can have other signs and symptoms common in Guillain-Barré syndrome, such as muscle weakness.Guillain-Barré syndrome occurs in people of all ages. The development of the condition usually follows a pattern. Prior to developing the condition, most people with Guillain-Barré syndrome have a bacterial or viral infection. The first phase of Guillain-Barré syndrome, during which signs and symptoms of the condition worsen, can last up to four weeks, although the peak of the illness is usually reached in one to two weeks. During the second phase, called the plateau, signs and symptoms of Guillain-Barré syndrome stabilize. This phase can last weeks or months. During the recovery phase, symptoms improve. However, some people with Guillain-Barré syndrome never fully recover and can still experience excessive tiredness (fatigue), muscle weakness, or muscle pain.

MalaCards based summary : Guillain-Barre Syndrome, also known as guillain-barré syndrome, is related to pharyngeal-cervical-brachial variant of guillain-barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy, and has symptoms including seizures, tremor and back pain. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Measles. The drugs Pharmaceutical Solutions and 4-Aminopyridine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and eye, and related phenotypes are acute demyelinating polyneuropathy and hyporeflexia

Disease Ontology : 12 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

GARD : 20 Guillain-Barre syndrome (GBS) is a rare syndrome in which the body's immune system attacks part of the peripheral nervous system. The peripheral nervous system carries signals from the brain to the muscles. Symptoms of GBS include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all ( paralysis ). The exact cause of Guillain-Barre syndrome is unknown. In most cases, GBS occurs a few days or weeks after symptoms of a viral infection. In rare cases, GBS may run in families. A diagnosis of GBS is suspected when a person has symptoms suggestive of the syndrome. A variety of tests, including a spinal tap, may be completed to confirm the diagnosis. Treatment options may include plasma exchange (plasmapheresis) and immunoglobulin therapy.

MedlinePlus : 42 Guillain-Barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (PNS). The PNS nerves connect your brain and spinal cord with the rest of your body. Damage to these nerves makes it hard for them to transmit signals. As a result, your muscles have trouble responding to your brain. No one knows what causes the syndrome. Sometimes it is triggered by an infection, surgery, or a vaccination. The first symptom is usually weakness or a tingling feeling in your legs. The feeling can spread to your upper body. In severe cases, you become almost paralyzed. This is life-threatening. You might need a respirator to breathe. Symptoms usually worsen over a period of weeks and then stabilize. Guillain-Barre can be hard to diagnose. Possible tests include nerve tests and a spinal tap. Most people recover. Recovery can take a few weeks to a few years. Treatment can help symptoms, and may include medicines or a procedure called plasma exchange. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Guillain-Barré (Ghee-YAN Bah-RAY) syndrome (GBS) is a rare, autoimmune disorder in which a person's own immune system damages the nerves, causing muscle weakness and sometimes paralysis. GBS can cause symptoms that last for a few weeks to several years. Most people recover fully, but some have permanent nerve damage. Some people have died of GBS.

NINDS : 53 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barré syndrome. It is characterized by abnormal muscle coordination, paralysis of the eye muscles, and absence of the tendon reflexes. Like Guillain-Barré syndrome, symptoms may be preceded by a viral illness. Additional symptoms include generalized muscle weakness and respiratory failure. The majority of individuals with Miller Fisher syndrome have a unique antibody that characterizes the disorder.

KEGG : 36 Fisher syndrome is a variant of the Guillain- Barre syndrome (GBS) and its classical clinical triad consists of ophthalmoplegia, ataxia, and areflexia. It is a relatively rare neurological disorder, accounting for approximately 5% of acute inflammatory polyneuropathies. This disease is an immune-mediated condition and specific anti-ganglioside antibodies, especially IgG anti-GQ1b antibodies, are found in over 80% of the patients. Campylobacter and Haemophilus influenzae have been reported as infectious agents prior to the onset of Fisher syndrome. It has been reported that the median period required for the disappearance of ataxia was about 1 month, without therapy.

Wikipedia : 73 Guillain-Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the... more...

Related Diseases for Guillain-Barre Syndrome

Diseases in the Guillain-Barre Syndrome family:

Guillain-Barre Syndrome, Familial

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 992)
# Related Disease Score Top Affiliating Genes
1 pharyngeal-cervical-brachial variant of guillain-barre syndrome 32.8 HP ACP1
2 chronic inflammatory demyelinating polyradiculoneuropathy 32.1 PMP22 MPZ MBP IL17A HLA-DRB1 ALB
3 demyelinating polyneuropathy 31.7 PMP22 HP ALB
4 polyneuropathy 31.6 TNF PMP22 MPZ MBP ALB
5 polyradiculoneuropathy 31.4 PMP22 MPZ MBP IL17A ALB
6 polyradiculopathy 31.2 MBP DAAM2
7 aspiration pneumonia 31.1 TNF IL17A ALB
8 mumps 31.1 TNF HLA-DRB1 HLA-DQB1
9 peripheral nervous system disease 31.1 TNF PMP22 PMP2 MPZ MOG MBP
10 foot drop 31.0 PMP22 MPZ
11 neuropathy 30.9 TNF PMP22 PMP2 MPZ MBP ALB
12 hereditary neuropathies 30.9 PMP22 MPZ MBP
13 critical illness polyneuropathy 30.7 TNF ALB
14 lupus erythematosus 30.7 TNFRSF1B TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
15 mononeuropathy 30.7 TNF PMP22 MPZ ALB
16 viral hepatitis 30.7 TNF HLA-DRB1 HLA-DQA1 ALB
17 myelitis 30.6 TNF MOG MBP IL17A
18 membranous nephropathy 30.6 TNF HLA-DQA1 CD79A ALB
19 thyroiditis 30.6 TNF IL17A HLA-DRB1
20 reactive arthritis 30.6 TNF IL17A HP HLA-DRB1
21 temporal arteritis 30.6 TNF IL17A HLA-DRB1
22 lyme disease 30.6 TNF IL17A HLA-DRB1 HLA-DQB1
23 meningitis 30.6 TNF IL17A ICAM1 ALB
24 typhoid fever 30.5 TNF HLA-DRB1 HLA-DQB1 GALE ALB
25 pemphigoid 30.5 TNF HLA-DRB1 HLA-DQB1
26 leishmaniasis 30.5 TNF IL17A HLA-DRB1 HLA-DQB1 HLA-DQA1
27 pulmonary tuberculosis 30.5 TNF HP HLA-DRB1 HLA-DQB1 ALB
28 transverse myelitis 30.5 TNF MOG MBP IL17A
29 echinococcosis 30.5 TNF IL17A HLA-DRB1
30 graft-versus-host disease 30.5 TNF HLA-DRB1 HLA-DQB1
31 disease by infectious agent 30.5 TNF IL17A HP CD1A ALB
32 churg-strauss syndrome 30.5 TNF IL17A HLA-DRB1
33 visceral leishmaniasis 30.4 TNF ICAM1 HLA-DRB1 HLA-DQA1 ALB
34 allergic encephalomyelitis 30.4 MOG MBP
35 proteasome-associated autoinflammatory syndrome 1 30.4 TNF IL17A ICAM1 ALB
36 psoriatic arthritis 30.4 TNFRSF1B TNF IL17A HLA-DRB1
37 bacterial meningitis 30.4 TNF IL17A ALB
38 spondyloarthropathy 1 30.4 TNFRSF1B TNF IL17A HP
39 endocarditis 30.4 TNF IL17A ALB
40 pharyngitis 30.4 TNF HLA-DRB1 CD1A
41 bacterial pneumonia 30.4 TNF IL17A ALB
42 glomerular disease 30.3 CD79A ALB
43 panuveitis 30.3 TNF IL17A HLA-DRB1 HLA-DQB1
44 vasculitis 30.3 TNF IL17A ICAM1 CD79A
45 cryoglobulinemia 30.3 TNF HLA-DRB1 CD79A
46 myositis 30.3 TNF IL17A HLA-DRB1 HLA-DQA1
47 vogt-koyanagi-harada disease 30.3 IL17A HLA-DRB1 HLA-DQB1 HLA-DQA1
48 common variable immunodeficiency 30.3 TNFRSF1B TNF HLA-DRB1 HLA-DQB1 CD79A
49 keratoconjunctivitis sicca 30.3 TNF CD79A ALB
50 sarcoidosis 1 30.3 TNFRSF1B TNF ICAM1 HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:



Diseases related to Guillain-Barre Syndrome

Symptoms & Phenotypes for Guillain-Barre Syndrome

Human phenotypes related to Guillain-Barre Syndrome:

31 (show all 12)
# Description HPO Frequency HPO Source Accession
1 acute demyelinating polyneuropathy 31 obligate (100%) HP:0007131
2 hyporeflexia 31 frequent (33%) HP:0001265
3 distal lower limb muscle weakness 31 frequent (33%) HP:0009053
4 generalized hypotonia 31 frequent (33%) HP:0001290
5 unsteady gait 31 frequent (33%) HP:0002317
6 recurrent fever 31 frequent (33%) HP:0001954
7 impaired oropharyngeal swallow response 31 frequent (33%) HP:0031162
8 drooling 31 frequent (33%) HP:0002307
9 dysesthesia 31 frequent (33%) HP:0012534
10 emg: neuropathic changes 31 frequent (33%) HP:0003445
11 sleepy facial expression 31 frequent (33%) HP:0005335
12 onion bulb formation 31 occasional (7.5%) HP:0003383

UMLS symptoms related to Guillain-Barre Syndrome:


seizures; tremor; back pain; ophthalmoplegia; headache; syncope; pain; chronic pain; sciatica; vertigo/dizziness; sleeplessness; cerebellar ataxia; neuralgia

GenomeRNAi Phenotypes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB CD1A CD79A HLA-DQA1 IL17A MOG

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 ACP1 ALB CD79A HLA-DQB1 HP ICAM1
2 homeostasis/metabolism MP:0005376 10.03 ACP1 ALB CD79A DAAM2 HCRT HLA-DQB1
3 immune system MP:0005387 9.77 ACP1 ALB CD79A HLA-DQA1 HLA-DQB1 HP
4 muscle MP:0005369 9.32 ACP1 ALB DAAM2 HCRT HLA-DQB1 ICAM1

Drugs & Therapeutics for Guillain-Barre Syndrome

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pharmaceutical Solutions Phase 2, Phase 3
2
4-Aminopyridine Approved Phase 2 504-24-5 1727
3
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
4 Complement System Proteins Phase 2
5 Potassium Channel Blockers Phase 2
6 Hormones Phase 2
7 glucocorticoids Phase 2
8 Hormone Antagonists Phase 2
9 Anti-Inflammatory Agents Phase 2
10 Antineoplastic Agents, Hormonal Phase 2
11 Immunoglobulin G Phase 2
12
Sodium citrate Approved, Investigational 68-04-2
13
Tryptophan Approved, Nutraceutical, Withdrawn 73-22-3 6305
14
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
15 Hemostatics
16 Psychotropic Drugs
17 Antidepressive Agents
18 Citrate
19 Vaccines
20 Calcium, Dietary
21 Autoantibodies
22 pyruvate
23 Immunoglobulins
24 Immunoglobulins, Intravenous
25 Antibodies
26 Immunologic Factors
27 Rho(D) Immune Globulin
28 gamma-Globulins
29
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
2 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
3 A Randomized, Double-blind, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome Recruiting NCT04701164 Phase 2, Phase 3 ANX005;Placebo
4 A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS) Not yet recruiting NCT04752566 Phase 3 Placebo
5 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
6 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome Patients in Bangladesh: A Safety and Feasibility Study Completed NCT02780570 Phase 2
7 Efficacy and Safety of Preventive Mechanical Ventilation in Adults With Guillain Barré Syndrome Completed NCT00167622 Phase 2
8 Assessment of Chronic GBS Improvement With Use of 4-AP Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
9 A PROSPECTIVE, MULTI-CENTER, PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH GUILLAIN-BARRÉ SYNDROME Completed NCT02493725 Phase 2 Eculizumab;Placebo
10 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
11 An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients Recruiting NCT03943589 Phase 2 Imlifidase
12 A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome Recruiting NCT04035135 Phase 1 ANX005;Intravenous immunoglobulin
13 Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS) Not yet recruiting NCT03773328 Phase 1
14 A Prospective Interventional Study to Investigate Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation With or Without Coagulation Factors Replacement Unknown status NCT03801135 Fibrinogen concentrate
15 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
16 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
17 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
18 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
19 Immunoadsorption or Plasma Exchange - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases Completed NCT04687332
20 Risk of Guillain-Barré Syndrome Following Meningococcal Conjugate (MCV4) Vaccination Completed NCT00575653
21 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome : A Randomized Controlled Trial Completed NCT02883270
22 Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome. Completed NCT01024088
23 Comparison of Intravenous Immunoglobulin and Plasma Exchange in Treatment of Mechanically Ventilated Children With Guillain Barre Syndrome. A Randomized Study. Completed NCT01306578 IVIG
24 The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat) Completed NCT03710278
25 A Feasibility Study for Daily Use of a Brain Computer Interface for Communication in an ICU Completed NCT01005524
26 Regional Citrate Anticoagulation in Plasma Exchange Treatment Completed NCT01370200
27 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Completed NCT03941184
28 Recovery of Visual Acuity in Vestibular Deficits Completed NCT00411216
29 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Completed NCT03206541
30 International GBS Outcome Study (IGOS): A Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS). Recruiting NCT01582763
31 Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome (FOCUS on GBS) Recruiting NCT04829526
32 An Observational Cohort Study on the Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome Recruiting NCT04303962
33 New Biomarkers in Acute and Chronic Inflammatory Demyelinating Polyradiculoneuropathies Recruiting NCT04249752
34 Early Prediction of Respiratory and Autonomic Complications of GBS Using Neuromuscular Ultrasound Recruiting NCT04166357
35 Neurology Inpatient Clinical Education Trial Active, not recruiting NCT03826056
36 Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome: A Pilot Study Enrolling by invitation NCT04053452
37 Processing Integration in Neurological Patients Using fMRI Not yet recruiting NCT02722070
38 Efficacy of Mini-pool Intravenous Immunoglobulin (MP-IVIG) Prepared by Assiut University Hospital Blood Bank in Guillain-Barré Syndrome Not yet recruiting NCT04550611
39 NEUROKINASE : Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases. Not yet recruiting NCT04674163
40 Neuromuscular Ultrasound Changes in Neuropathies in Correlation to Neurophysiological Findings Not yet recruiting NCT04092140
41 Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome Terminated NCT00004833 Immune globulin
42 Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome Withdrawn NCT02459808
43 Feasibility of Two Novel Interactive Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments Using the YouGrabber Training System - the KAYO Study Protocol Withdrawn NCT03268304

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Immunoglobulins, Intravenous

Cochrane evidence based reviews: guillain-barre syndrome

Genetic Tests for Guillain-Barre Syndrome

Anatomical Context for Guillain-Barre Syndrome

MalaCards organs/tissues related to Guillain-Barre Syndrome:

40
Spinal Cord, Brain, Eye, T Cells, Lung, Bone, Kidney

Publications for Guillain-Barre Syndrome

Articles related to Guillain-Barre Syndrome:

(show top 50) (show all 9204)
# Title Authors PMID Year
1
Peripheral Nervous System Manifestations Associated with COVID-19. 61 42
33586020 2021
2
Guillain-Barré syndrome triggered by surgery in a Chinese population: a multicenter retrospective study. 42 61
33509120 2021
3
Treatment-related Fluctuations in Guillain Barre Syndrome and the Conundrum of Additional Cycles of Plasmapheresis. 20 61
29184340 2017
4
Electrophysiological features of acute inflammatory demyelinating polyneuropathy associated with SARS-CoV-2 infection. 42
33685769 2021
5
Hypocretin/orexin and narcolepsy: new basic and clinical insights. 61 54
19555382 2010
6
[Evaluation of myelin basic protein levels with receiver operating characteristic curves for diagnosis of multiple sclerosis]. 61 54
19246291 2009
7
Guillain-Barré syndrome. 61 54
16271648 2005
8
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. 61 54
16170091 2005
9
Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. 61 54
15979356 2005
10
Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. 54 61
14653854 2004
11
Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. 61 54
12676332 2003
12
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. 54 61
11912115 2002
13
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. 61 54
11756606 2001
14
Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. 54 61
11438177 2001
15
Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases. 61 54
11200685 2000
16
Anti-PMP22 antibodies in patients with inflammatory neuropathy. 61 54
10713353 2000
17
[Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies]. 61 54
10377820 1999
18
T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome. 61 54
9455979 1997
19
Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis. 54 61
8707926 1996
20
[Anti-glycoconjugate antibodies and dysglobulinemic or dysimmune peripheral neuropathies]. 61 54
8881439 1996
21
Anti-alpha- and beta-tubulin IgM antibodies in dysimmune neuropathies. 61 54
8583236 1995
22
Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. 54 61
7905957 1994
23
Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. 61 54
7689591 1993
24
T cell responses to myelin proteins in Guillain-Barré syndrome. 54 61
1279128 1992
25
In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes. 61 54
1718212 1991
26
Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. 61 54
2094193 1990
27
Antibodies to gangliosides and myelin proteins in Guillain-Barré syndrome. 54 61
2194427 1990
28
Characterization of the anti-α-Gal antibody profile in association with Guillain-Barré syndrome, implications for tick-related allergic reactions. 61
33465663 2021
29
Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system. 61
33533072 2021
30
Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: A case report and review of the literature. 61
33748382 2021
31
Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay. 61
33811309 2021
32
The SARS-CoV-2 as an instrumental trigger of autoimmunity. 61
33610751 2021
33
Changes in motor nerve excitability in acute phase Guillain-Barré syndrome. 61
33452679 2021
34
Preventing expensive harms in Guillain-Barré syndrome. 61
33743227 2021
35
Coronavirus Disease 2019 and the Risk of Guillain-Barré Syndrome. 61
33394537 2021
36
SARS-CoV-2 associated Guillain-Barré syndrome. 61
32770414 2021
37
Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with guillain-barré syndrome, a single center experience. 61
33775352 2021
38
The Zika virus: Lurking behind the COVID-19 pandemic? 61
33217046 2021
39
Reply to "Guillain‑Barré syndrome in the COVID‑19 era another occasional cluster?": Insights from two distinct clusters of Guillain-Barré syndrome detected in Europe in the COVID-19 era. 61
32749602 2021
40
Guillain-Barré syndrome in the COVID-19 era: another occasional cluster? 61
32577868 2021
41
Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. 61
32840686 2021
42
Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster? 61
32430572 2021
43
Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature. 61
33640717 2021
44
Cerebrospinal Fluid Analysis. 61
33788511 2021
45
Guillain Barre Syndrome following delivery in a pregnant woman infected with SARS-CoV-2. 61
33775326 2021
46
Lymphocyte-based ratios for predicting respiratory failure in Guillain-Barré syndrome. 61
33548620 2021
47
Acute immune sensory polyradiculopathy: a new variant of Guillain-Barré syndrome. 61
33347623 2021
48
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. 61
33743237 2021
49
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy. 61
33170339 2021
50
Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. 61
33462778 2021

Variations for Guillain-Barre Syndrome

Expression for Guillain-Barre Syndrome

Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for Guillain-Barre Syndrome

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 TNFRSF1B TNF IL17A ICAM1 HLA-DRB1 HLA-DQB1
2
Show member pathways
12.68 TNF ICAM1 HLA-DRB1 HLA-DQB1 HLA-DQA1
3
Show member pathways
12.65 TNF IL17A ICAM1 HLA-DRB1 HLA-DQB1 HLA-DQA1
4
Show member pathways
12.41 TNF IL17A HLA-DRB1 HLA-DQB1 HLA-DQA1
5
Show member pathways
12.29 TNFRSF1B TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 CD79A
6
Show member pathways
12.11 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
7 12.08 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
8 12.06 TNF ICAM1 HLA-DRB1 HLA-DQB1 HLA-DQA1
9 11.76 TNFRSF1B TNF IL17A ICAM1
10 11.73 MPZ ICAM1 HLA-DRB1 HLA-DQB1 HLA-DQA1
11 11.65 ICAM1 HLA-DRB1 HLA-DQB1 HLA-DQA1
12
Show member pathways
11.59 HLA-DRB1 HLA-DQB1 HLA-DQA1
13 11.57 HLA-DRB1 HLA-DQB1 HLA-DQA1
14 11.38 TNFRSF1B TNF ICAM1
15 11.35 TNF ICAM1 HP
16 11.35 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 CD1A
17 11.07 TNF IL17A ICAM1 HLA-DRB1 HLA-DQB1 HLA-DQA1

GO Terms for Guillain-Barre Syndrome

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle membrane GO:0030666 9.63 HLA-DRB1 HLA-DQB1 HLA-DQA1
2 ER to Golgi transport vesicle membrane GO:0012507 9.61 HLA-DRB1 HLA-DQB1 HLA-DQA1
3 transport vesicle membrane GO:0030658 9.58 HLA-DRB1 HLA-DQB1 HLA-DQA1
4 membrane raft GO:0045121 9.55 TNFRSF1B TNF ICAM1 CD79A CD1A
5 myelin sheath GO:0043209 9.54 PMP2 MPZ MBP
6 clathrin-coated endocytic vesicle membrane GO:0030669 9.5 HLA-DRB1 HLA-DQB1 HLA-DQA1
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.43 HLA-DRB1 HLA-DQB1 HLA-DQA1
8 external side of plasma membrane GO:0009897 9.17 TNF MOG IL17A ICAM1 HLA-DRB1 CD79A
9 MHC class II protein complex GO:0042613 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.87 IL17A HP HLA-DRB1 HLA-DQB1 HLA-DQA1 CD79A
2 chemical synaptic transmission GO:0007268 9.8 PMP22 MPZ MBP HCRT
3 T cell receptor signaling pathway GO:0050852 9.73 MOG HLA-DRB1 HLA-DQB1 HLA-DQA1
4 adaptive immune response GO:0002250 9.73 IL17A HLA-DRB1 HLA-DQB1 HLA-DQA1 CD79A CD1A
5 positive regulation of interleukin-6 production GO:0032755 9.69 TNF MBP IL17A
6 antigen processing and presentation GO:0019882 9.58 HLA-DRB1 HLA-DQB1 HLA-DQA1
7 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.48 TNF MBP
8 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.46 HLA-DRB1 HLA-DQB1
9 interferon-gamma-mediated signaling pathway GO:0060333 9.46 ICAM1 HLA-DRB1 HLA-DQB1 HLA-DQA1
10 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.37 HLA-DRB1 HLA-DQB1
11 immune response GO:0006955 9.23 TNFRSF1B TNF MBP IL17A HLA-DRB1 HLA-DQB1
12 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1

Molecular functions related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1
2 MHC class II receptor activity GO:0032395 8.8 HLA-DRB1 HLA-DQB1 HLA-DQA1

Sources for Guillain-Barre Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....